HSA
NVAX icon

Hussman Strategic Advisors’s Novavax NVAX Stock Holding History

Hussman Strategic Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-42,000
Closed -$342K – 296
2026
Q1 		$342K Buy
+42,000
New +$381K 0.07% 241
2025
Q2 		– Sell
-168,000
Closed -$1.08M – 269
2025
Q1 		$1.08M Buy
168,000
+84,000
+100% +$694K 0.26% 156
2024
Q4 		$675K Hold
84,000
– – 0.2% 169
2024
Q3 		$1.06M Buy
+84,000
New +$1.08M 0.26% 155
2020
Q2 		– Sell
-15,000
Closed -$204K – 301
2020
Q1 		$204K Buy
+15,000
New +$127K 0.06% 257

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Hussman Strategic Advisors's NVAX Position: Q2 2026 in Review

Hussman Strategic Advisors sold out of Novavax (NVAX) in Q2 2026, closing a stake of 42,000 shares — an estimated $342K sold.

Hussman Strategic Advisors first reported a position in NVAX in Q1 2020 and held it in 5 quarters. The position peaked at $1.08M in Q1 2025. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Hussman Strategic Advisors reported no remaining Novavax position as of Q2 2026 after selling out during the quarter.
  • Hussman Strategic Advisors sold 42,000 Novavax shares in Q2 2026, an estimated $342K.
  • Hussman Strategic Advisors first reported a position in Novavax in Q1 2020 and held it in 5 quarters.
  • Hussman Strategic Advisors's Novavax position peaked at $1.08M in Q1 2025.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.